title: Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol.
abstract: Lymphoseek is a receptor-binding radiopharmaceutical specifically designed for sentinel lymph node (SLN) mapping. We conducted a clinical trial which measured the injection site clearance and sentinel lymph node accumulation after a single intradermal injection of Lymphoseek or unfiltered [(99m)Tc]sulfur colloid (TcSC) using a "2-day" protocol for SLN mapping of breast cancer. Eleven patients with breast cancer participated in this study. Five patients received an intradermal administration of 1.0 nmol of (99m)Tc-labeled Lymphoseek; SLN mapping was performed on four subjects within 19 to 27 h. Six subjects received an intradermal administration of TcSC; SLN mapping was performed on five subjects within 18 to 26 h. Lymphoseek exhibited a significantly (P<.001) faster injection site clearance than TcSC. The mean Lymphoseek clearance half-time was 2.18+/-1.09 h compared to 57.4+/-92.8 h for TcSC. The mean sentinel lymph node uptake of Lymphoseek (1.5+/-1.7%) and TcSC (3.5+/-3.1%) was statistically equivalent (P=.213). When an intradermal injection is employed, Lymphoseek demonstrated faster injection site clearance than unfiltered [(99m)Tc]sulfur colloid and persistent SLN accumulation for at least 24 h.
authors: Department of Surgery, University of California, San Diego, CA 92103, USA; Moores UCSD Cancer Center, University of California, La Jolla, CA 92093, USA.
authors: Anne M
authors: AM
authors: Wallace
authors: Carl K
authors: CK
authors: Hoh
authors: Karl K
authors: KK
authors: Limmer
authors: Denise D
authors: DD
authors: Darrah
authors: Gery
authors: G
authors: Schulteis
authors: David R
authors: DR
authors: Vera
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D003911:Dextrans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008198:Lymph Nodes / Q000378:metabolism*; D008351:Mannans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011851:Radioactivity; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics*; D021701:Sentinel Lymph Node Biopsy; D016284:Technetium Tc 99m Pentetate / Q000031:analogs & derivatives; D013671:Technetium Tc 99m Sulfur Colloid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013997:Time Factors
chemical_list: D003911:Dextrans; D008351:Mannans; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C431884:technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran; D013671:Technetium Tc 99m Sulfur Colloid; D004369:Pentetic Acid; D016284:Technetium Tc 99m Pentetate